NCT05938725CompletedPhase 1/2
A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 2 Dec 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 7 Jun 2024
- Start date
- 20 Jul 2023
- Lead sponsor
- Kyverna Therapeutics Inc.
- Diseases
- Lupus (SLE)
- NCT number
- NCT05938725
- EU CT number
- 2024-513329-22-00
- EudraCT number
- 2022-003686-38
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 32
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitaetsklinikum Duesseldorf AöR Coordinator of this site? Confirm its status | Duesseldorf | Germany | Completed |
| Universitaetsklinikum Erlangen AöR Coordinator of this site? Confirm its status | Erlangen | Germany | Completed |
| Universitaetsklinikum Leipzig Aor Coordinator of this site? Confirm its status | Leipzig | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.